Second HealthTech call
25 January 2023
Leading innovation for the benefit of patients
A new funding opportunity to companies, research and healthcare organisations looking to work together to co-develop healthtech products or services at prototype stage and validate these solutions at a clinical level.
Based on the strength of the first Joint Call HealthTech, the Ministry of the Economy, the National Research Fund and Luxinnovation join forces again to further build the collaboration culture between companies, research and healthcare organisations. This includes matching HealthTech products or services at prototype stage with research and healthcare expertise to co-develop and validate these solutions at a clinical level for the benefit of patients and deliver leading innovation.
Call open from 1 February 2023 to 31 March 2023.
Innovative digital health solutions
The overall goal of this new joint healthtech call is the development and validation of innovative digital health solutions benefiting the national healthcare (patients, healthcare professionals, payers), research and innovation ecosystems.
The joint call intends to incentivise collaborative R&D projects for improvement of health and care delivery focused on medical evidence, harnessing the opportunities of digital health (mHealth, telemonitoring, AI, personalised medicine…) in order to enable a patient-centred healthcare.
It also aims to provide a financial incentive to consortia who have a specific digital product or service at prototype stage for which they wish to demonstrate its relevance and benefit for human health and society.
Topic of the call
Proposed solutions through this call should include the use of digital tools to improve prevention, diagnosis, monitoring or treatment of health conditions to improve public health or to increase patient autonomy, such as at home or in a care home environment.
Products to be developed through this call must be innovative digital health solutions for human use that (1) are already at prototype stage and that can meet at least one of (2a) or (2b):
- (2a) are or will be regulated by the medical device regulation (MDR)2 or in-vitro medical device regulation (IVDR)3. (Examples: digital medical devices, digital health applications, connected medical devices)
- (2b) that will apply innovative data processing or analysis techniques on real world data from healthcare or care environments to prove a societal impact.
In line with national priorities seeking to develop personalised medicine further, and in line with strategic intentions to build a data innovation service platform, consortia will have to align to the following approaches:
- Innovative clinical investigations: centred on taking the current state of the art in clinical trials and refining their design and implementation through innovative means such as digital tools, smart wearables and sensors, electronic medical record analysis, and other precision medicine approaches. These clinical trials should bring added value to patients.
- Multifactorial intervention strategies: focused on designing and testing interventions that are not molecular in nature, for example through lifestyle and digital means. The goal is to improve health through innovative, participatory, and personalised intervention strategies, resulting in health-associated impact through interdisciplinary research.
HealthTech call: information sessions
A webinar series presenting the objectives of the Joint Call HealthTech as well as the process of preparing applications, is organised. First session will be held on 2023, February 1 and will followed by a Q&A session.
Second HealthTech callBased on the strength of the first Joint Call HealthTech, the Ministry of the Economy, the National Research Fund and…
In conversation with our young researchers: Neera ChakrapaniHow can we better understand red meat allergy and the mechanism behind the delayed appearance of allergic symptoms? Neera Chakrapani…
Research Luxembourg Focus: Precision HealthWhat does the future of healthcare look like? Will artificial intelligence change the way we diagnose patients? Luxembourg has the…
SciLux podcast – Johannes Meiser, head of group at LIHHow can we target specific metabolic changes of cancer that would prevent the cancer cells proliferation? Dr Johannes Meiser is…
A brand new infrastructure to strengthen Luxembourg’s leading activities in translational medicinePersonalised healthcare is a priority of Luxembourg’s research and innovation strategy, making translational medecine a key discipline for research institutions…
In conversation with our young researchers: Agnieszka DemczukHow can we improve allergen-specific immunotherapy to better respond to allergic diseases? Agnieszka Demczuk is a PhD candidate in the…
SciLux podcast – Ibrahim Boussaad, research scientist at LCSBHow to identify key mechanism of Parkinson’s disease? Parkinson’s disease is a neurodegenerative disease that we are not able to…
In conversation with our young researchers: Charlotte StoffelsHow can we better understand potential negative impacts of PFAS on our health? Charlotte Stoffels is a PhD candidate in…
SciLux podcast – Camille Perchoux, research associate at LISERHow urban environments impact health? Characteristics where we live or where we travel on a daily basis have an influence…
A pioneering study using vocal biomarkers to monitor COVID-19The Predi-COVID Cohort study, a project led by Dr Guy Fagherazzi of the Luxembourg Institute of Health (LIH), showed for…